Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.55 |
| ▸ | FADS1 | O60427 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | LTK | P29376 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31747067 | 1.00 | KMT2A (0.57) | KMT2AMEN1EGFRFADS1MAPK1 | |
| SCHEMBL9017045 | 0.86 | TTBK1 (0.61) | KMT2AMEN1EGFRFADS1MAPK1 | |
| SCHEMBL17598134 | 0.85 | EGFR (0.57) | KMT2AMEN1EGFRFADS1MAPK1 | |
| SCHEMBL5564640 | 0.85 | HTT (0.62) | EGFRMAPK1HTTSMN1; SMN2ERBB2 | |
| SCHEMBL31747064 | 0.85 | EGFR (0.51) | EGFRFADS1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL31747065 | 0.85 | EGFR (0.51) | EGFRFADS1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL20355308 | 0.84 | SMN1; SMN2 (0.63) | KMT2AMEN1EGFRMAPK1HTT | |
| SCHEMBL2700855 | 0.83 | EGFR (0.64) | KMT2AMEN1EGFRFADS1MAPK1 | |
| SCHEMBL147559 | 0.83 | MEN1 (0.57) | KMT2AMEN1EGFRMAPK1HTT | |
| SCHEMBL31620745 | 0.80 | MEN1 (0.64) | KMT2AMEN1EGFRMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | KMT2A 1230/4885MEN1 1784/4885EGFR 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.